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A 48-years old man was diagnosed an IgD-k multiple myeloma (MM) at age 38 years for which he successfully underwent
chemotherapy and bone marrow transplant. He then developed a graft-versus-host disease (GVHD) whose manifestations
included, three years later, a polymyositis, diagnosed at muscle biopsy and successfully treated with steroids. Few months after
polymyositis remission, myeloma relapsed and the patient was treated with thalidomide for six years with good remission. Soon
after thalidomide suspension, MM relapsed again and the patient came to our observation for a new onset of neuromuscular
symptoms. He underwent both muscle and peripheral nerve biopsy to discriminate between myositis (paraproteinemia versus
GVHD), amyloidosis, and thalidomide toxicity. The first muscle biopsy showed an inflammatory pattern with necrotic fibres,
macrophagical invasion (CD68 positive), rare interstitial cellular infiltrates (CD8 positive and CD4 negative), widespread anti-
HLA positivity and negative antiMAC. The second muscle biopsy showed the same inflammatory pattern plus an involvement of
blood vessels. Direct immunofluorescence for IgD showed diﬀuse positivity along the sarcolemmal in both muscle biopsies. Sural
nerve biopsy demonstrated both demyelinating and axonal aspects with no inflammatory infiltrates, but positivity for HLA and
MAC. Congo Red was negative in both skeletal muscle and peripheral nerve.
IgD MM is a rare form of myeloma frequently associated
with amyloidosis. Myositis is often described as expression
of chronic GVHD, but not as a direct complication of MM.
Secondmuscle biopsy revealed an inflammatory pattern with
large amount of monoclonal proteins along the sarcolemma.
Vessel inflammatory signs were also evident in peripheral
nerve. This is the first case of concurrent polyneuropathy
and myositis in IgD MM. We hypothesize that the neuro-
myositis is caused by sarcolemmal deposits of IgD. The
presence of these deposits correlates with high blood levels
of monoclonal proteins.
IgD myeloma is a rare entity, accounting for 1-2% of
reported cases of multiple myeloma (MM) [1]. Association
between demyelinating polyneuropathy or myositis and MM
is known [2, 3]. Thalidomide, a treatment for refractory
oncologic diseases, causes a predominantly sensory axonal
neuropathy [4]. Myositis is a described complication of
graft-versus-host disease (GVHD) presenting in a fashion
similar to that of idiopathic myositis [5, 6]. Neuropathy may
occur in a context of MM during systemic acquired amy-
loidosis or due to autoimmune process or cryoglobulinemia
[7].
A 38-years-old man was diagnosed a IIA stadium IgD-k
(MM). He immediately underwent chemotherapy (two DAV
cycles and 4 ProMECE-CytaBOM cycles) and, one year later,
bone marrow transplant (BMT). One month after BMT he
developed a GVHD with skin and articular involvement.
When he was 41 years old he developed muscular symptoms
(myalgias and hyperCKemia). He underwent a skeletal
muscle biopsy which led to a diagnosis of polymyositis:
he was treated with steroids for some months and with
azathioprine for three years with complete disease remission.
At age of 42-years myeloma relapsed: the patient was
treated with thalidomide for six years with good clinical
remission, but progressively increasing levels of serum IgD
were demonstrated.
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Figure 1: (a) GT 100X, first biopsy: presence of a large interstitial infiltrate. (b) HE 100X, second biopsy: perivascular infiltrates, mild
increase of endomysial connective. (c) IgD immunofluorescence 250X, first biopsy: presence of immunoreactivity along the sarcolemma and
in the connective tissue. (d) IgD immunofluorescence 250X, second biopsy: strong reactivity in necrotic fibres and endomysial connective. (e)
IgD immunofluorescence in the negative control, 250X: aspecific signal. (f) IgD immunofluorescence in a case of vasculitis, 250X: aspecific
signal.
Six years later (at age of 48 years), the patient came to our
observation for a new onset of neuromuscular symptoms:
distal lower limb hypopallaesthesia, proximal limb hypotro-
phy, lower limb girdle weakness, hyperCKemia. Conduction
studies examination showed changes suggestive of axonal
polyneuropathy associated with a myopathic pattern on
needle EMG investigation.
He underwent both muscle and peripheral nerve
biopsy to discriminate between myositis (paraproteine-
mia versus GVHD), amyloidosis, and thalidomide toxic-
ity. Conventional histological/histochemical studies along
with immunohistochemistry for HLA, membrane attack
complex (MAC), and IgD, were performed on both skele-
tal muscle biopsies and peripheral nerve cryostat sec-
tions. CD8, CD4, CD19, and CD68 immunohistochem-
istry was performed on skeletal muscle only. The first
muscle biopsy showed an inflammatory pattern with
necrotic fibres, macrophage invasion (CD68 positivity),
rare interstitial cellular infiltrates, rare CD8 and absence
of CD4 lymphocytes, widespread sarcolemmal HLA pos-
itivity, and no MAC detection in capillaries. The second
muscle biopsy showed the same inflammatory pattern
seen in the previous one plus an involvement of blood
vessels (several perivascular cellular infiltrates in mus-
cle with mild MAC positivity) and a slight increase of
endomysial connective tissue. Sural nerve biopsy demon-
strated both demyelinating and axonal aspects. No inflam-
matory infiltrates, but positive immunohistochemistry for
HLA and MAC and dilated endoneurial capillaries were
observed.
Congo Red was negative in both skeletal muscle and
peripheral nerve.
Neurology Research International 3
Direct immunofluorescence for IgD was positive in both
muscle biopsies: in the first one, IgD mainly accumulated
along the sarcolemma; in the second one necrotic fibres
and endomorphism connective were also strongly reactive.
Conversely, nerve biopsy was IgD negative (see Figure 1).
MM is associated with amyloidosis. In our case, no
Congo Red positivity was observed in both muscle and
nerve tissues. Cryoglobulins were absent in serum and
autoimmune diseases were excluded by the absence of the
most common antibodies.
Myositis during chronic GVHD presents CD8-positive
interstitial infiltrates with rare macrophages [6]. Our
patient’s biopsies showed a predominance of macrophages:
these results do not favour GVHD diagnosis even if a
systemic involvement was evident when the first myositis
episode occured.
Thalidomide causes a neuropathy without inflammatory
signs [4]. In our patient, nerve biopsy showed a mixed
pattern with evidence of inflammation at immunohisto-
chemistry.
Kiprov and Miller [2] demonstrated IgG deposits along
basement membrane and myelin sheath in case of myositis
or demyelinating neuropathy during MM.
Given the presence of sarcolemmal and cytoplasmic
deposits of IgD in both muscle biopsies, we hypothesize that
myositis in our patient is paraproteinemia-correlated. The
presence of IgD deposits correlates with high blood levels of
monoclonal proteins at least in the second episode.
Conversely, polyneuropathy could be caused by thalido-
mide, though inflammation cannot be excluded (HLA and
MAC positivity) even if we did not observe IgD deposits.
This is the first case of concurrent polyneuropathy
and myositis in IgD MM. In our patient neuromuscular
symptoms subsided after steroid therapy.
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